Overview
Molecular Tumor Board at the Center for Personalized Medicine
Description
Molecular Tumor Board at the Center for Personalized Medicine The study objectives are
- To ensure a prospective documentation of all patients who are referred to the Molecular Tumor Board in routine clinical care
- To prospectively ensure the documentation of MTB patients with an emphasis to clinical outcome parameters progression-free survival (PFS), overall survival (OS) and further response assessments (e.g. peripheral immunmonitoring, imaging parameters)
- To prospectively assess patient-reported outcome of MTB patients
- To evaluate compliance to MTB suggestions in routine clinical care
Eligibility
Inclusion Criteria:
- Given informed consent ("broad consent" of the University Hospital Tübingen)
- ≥ 18 years of age
- Clinical indication for a referral to Molecular Tumor Board by the treating physician
Exclusion Criteria:
- The MTB assists the referring physician with the interpretation and the use of tumor molecular profiling data for deciding on a therapeutic strategy. Therefore, this board is confined to cancer patients and cannot provide any service for non-cancer patients